Biologics (mAbs) specifically targeting type 2 immune pathways have provided clinical benefit in reducing the frequency of asthma exacerbations and there are now several approved for use in asthma including omalizumab (anti-IgE mAb)42,43, dupilumab (anti-IL-4Rα)6,44, mepolizumab and reslizumab (anti-IL-5)10,45–48 and benralizumab (anti-IL-5R)49,50. Here, IL5 is linked to asthma.